Evidence map›Paper›PMID 39805874›Full record

ArticleNPJ vaccines2025

A broad spectrum Shigella vaccine based on VirG

Girmay Desalegn, Charlotte Abrahamson, K Ross Turbyfill, Lucy Pill-Pepe, Leslie Bautista, Chitradevi S Tamilselvi, Dylan Dunn, Neeraj Kapoor, Barbara Sullinger, Matheo Herrera and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in NPJ vaccines, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. bioRxiv : the preprint server for biology · 2026
    Article
  3. Review
  4. Article
  5. Characterization ofApplied and environmental microbiology · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Girmay Desalegn *Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, USA.ORCID http://orcid.org/0000-0001-8150-1277
Charlotte Abrahamson *Vaxcyte Inc., San Carlos, CA, USA.ORCID http://orcid.org/0000-0001-8201-995X
K Ross Turbyfill *Department of Diarrheal Disease Research, Bacterial Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, MD, USA.
Lucy Pill-PepeVaxcyte Inc., San Carlos, CA, USA.
Leslie BautistaVaxcyte Inc., San Carlos, CA, USA.
Chitradevi S TamilselviCenter for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, USA.
Dylan DunnCenter for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, USA.ORCID http://orcid.org/0009-0001-8158-5201
Neeraj KapoorVaxcyte Inc., San Carlos, CA, USA.ORCID http://orcid.org/0000-0001-7888-6452
Barbara SullingerVaxcyte Inc., San Carlos, CA, USA.
Matheo HerreraVaxcyte Inc., San Carlos, CA, USA.
Edwin V OaksDepartment of Diarrheal Disease Research, Bacterial Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, MD, USA.
Jeff FairmanVaxcyte Inc., San Carlos, CA, USA.ORCID http://orcid.org/0000-0001-5763-2867
Marcela F PasettiCenter for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, USA. mpasetti@som.umaryland.edu.ORCID http://orcid.org/0000-0003-0894-4009

Funding

Broad spectrum Shigella subunit vaccine based on conserved proteinsR01AI161839 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI PASETTI, MARCELA F · 2021 to 2025
$2.6M
NIAID NIH HHS R01 AI161839NIH HHS R01-AI161839
6 · The paper itself

Abstract

Dysentery caused by Shigella species remains a major health threat to children in low- and middle-income countries. There is no vaccine available. The most advanced candidates, i.e., O-polysaccharide (OPS)-based conjugates, have limited coverage-only against the immunizing serotype. Vaccines based on Shigella conserved proteins are sought for their simplicity and capacity to prevent disease caused by multiple serotypes. We previously reported the broad protective capacity of VirGα, a conserved surface-exposed domain of Shigella virulence factor. Seeking to refine the vaccine antigenic target and achieve scalable manufacturing compatible with Good Manufacturing Practices, we mapped linear B-cell epitopes spanning the entire VirG protein sequence by probing the immune reactivity of 10-mer peptides (overlapping 4-8 aa) with sera from Shigella-infected rhesus monkeys. The surface-exposed VirG

Identifiers

PMID39805874
PMCPMC11731012

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.